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Background	  to	  the	  study	  
• 	  Alzheimer’s	  disease	   (AD)	   is	   the	  most	   common	  
cause	   of	   demenOa	   and	   affects	   nearly	   40,000	  
individuals	  in	  Ireland.	  
• 	  The	  β-­‐amyloid	  pepOde	  (Aβ)	  plays	  a	  key	  role	   in	  
the	  pathogenesis	  of	  the	  AD	  and	  the	  presence	  of	  
Aβ	  plaques	  in	  the	  brain	  is	  diagnosOc.	  
• The	   hypothesis	   posits	   that	   Aβ  deposiOon	   is	   a	  
criOcal	   factor	   in	   the	   disease	   process	   and	   that	  
producOon	  and	  clearance	  of	  Aβ  are	  key	  drivers	  
of	  the	  disease1.	  	  
• Flux	   of	   Aβ  from	   the	   brain	   is	   believed	   to	  
contribute	   to	   the	   overall	   level	   of	   Aβ  within	   in	  
brain2	   and	   anObody	   mediated	   brain-­‐to-­‐blood	  
efflux	  has	  been	  observed	  in	  animal	  models3.	  	  
• Clearance	   of	   from	   the	   blood	   is	   believed	   to	   be	  
mainly	  via	  the	  liver,	  kidney	  and	  spleen4.	  
• Data	   from	   human	   studies	   indicate	   that	   the	  
about	   6%	   of	   the	   Aβ	   pool	   present	   in	   the	  
cerebrospinal	  fluid	  is	  cleared	  per	  hour5.	  
• There	  are	  no	  data	  available	  on	  the	  magnitude	  of	  
the	  cerebral	  output	  of	  Aβ pepOdes	  in	  man	  or	  the	  
hepaOc	  uptake.	  
• The	   aim	   of	   this	   work	   was	   to	   invesOgate	   if	   the	  
concentraOon	  Aβ  pepOdes	  is	  different	  in	  jugular	  
venous	   plasma	   and	   arterial	   plasma	   and	   so	  
esOmate	  direct	  values	  for	  both	  brain-­‐to-­‐blood	  Aβ 
efflux	  and	  hepaOc	  clearance	  in	  man.	  
Figure	   2.	  Mechanism	   of	   transport	   of	   Aβ  across	   the	  
blood-­‐brain	  barrier.	  Aβ produced	  in	  the	  brain	  becomes	  
bound	   to	   apolipoproteins	   within	   the	   brain	   intersOOal	  
fluid.	  Brain	  microvascular	  endothelial	  cells	  can	  take	  up	  
APOE-­‐Aβ	   and	   APOJ-­‐Aβ	   complexes	   via	   mechanisms	  
dependent	  on	  LRP1	  or	  LRP2,	   respecOvely.	   Intracellular	  
Aβ	   may	   then	   be	   effluxed	   into	   the	   circulaOon	   via	   a	  
process	   involving	  ABCB1	  where	  the	  Aβ  may	  either	  be	  
degreaded	   peripherally	   or	   become	   subjected	   to	   RAGE	  
dependent	  uptake.	  This	   lafer	  process	   leads	   to	   the	   re-­‐
entry	   of	   Aβ  into	   the	   brain	   and	   is	   effecOvely	   a	   fuOle	  
cycle.	   APOE=apolipoprotein	   E;	   APOJ=apolipoprotein	   J;	  
LRP1=low	  density	   lipoprotein	   receptor	   related	   protein	  
1;	   LRP2=low	   density	   lipoprotein	   receptor	   related	  
protein	  2;	  ABCB1=ATP	  binding	  cassefe	  transporter	  B1;	  
RAGE=receptor	  for	  advanced	  glycaOon	  endproducts.	  
Figure	  1.	  Model	  of	  Aβ	   fluxes	   in	  man.	  Aβ	   produced	   in	   the	  
brain	   passes	   into	   the	   blood,	   either	   directly	   across	   the	  
blood-­‐brain	  barrier	  or	  via	  the	  cerebrospinal	  fluid	  (CSF).	  It	  is	  
carried	  in	  a	  complex	  with	  numerous	  different	  proteins.	  The	  
liver,	  kidney	  and	  spleen	  can	  take	  up	  and	  metabolise	  Aβ	  via	  
various	   proteases.	   LRP1=low	   density	   lipoprotein	   receptor	  
related	   protein	   1;	   Alb=albumin;	   TTR=transthyreOn;	  
AAT=α1-­‐anOprotease;	   NEP=	   nephyrilisin;	   IDE=insulin	  



























• Blood	  samples	  were	  obtained	  as	  described6.	   • Plasma	  samples:	  These	  were	  available	   in	  connecOon	  with	  
a	  previous	  study	  on	  brain	  sterol	  fluxes6.	  Briefly,	  ten	  healthy	  
males,	   mean	   age	   29	   years	   (range,	   21–38	   years)	   were	  
recruited	  for	  this	  study	  and	  blood	  samples	  were	  taken	  aker	  
an	   overnight	   fast.	   	   Plasma	   was	   frozen	   at	   -­‐80°C	   unOl	  
required	  for	  analysis.	  
• Ethics:	   All	   experiments	   involving	   human	   volunteers	   were	  
reviewed	   and	   approved	   by	   the	   ethics	   commifees	   at	   the	  
Huddinge	  Hospital	  and	  the	  Karolinska	  Hospital.	  ParOcipants	  
gave	  informed	  consent	  to	  parOcipate	  in	  the	  study	  
• ELISA	   for	  Aβ:	   Specific	  anObodies	  against	  Aβx-­‐40	   and	  Aβx-­‐42	  
were	   used	   as	   primary	   anObodies.	   	   The	   reporter	   anObody	  
was	   horseradish-­‐peroxidase-­‐linked	   anO-­‐rabbit	   IgG	   	   and	  
colour	   was	   developed	   with	   o-­‐phenylenediamine.	   The	  
detecOon	  limit	  for	  syntheOc	  Aβx-­‐40	  and	  Aβx-­‐42	  was	  1	  pM.	  All	  
samples	  were	  analyzed	  in	  the	  linear	  range	  of	  the	  ELISA.	  
Data	  Analysis:	  The	  concentraOon	  of	  Aβx-­‐40	  and	  Aβx-­‐42	  
in	  the	  arterial	  and	  venous	  plasma	  was	  compared	  using	  
a	  non-­‐parametric	  approach.	  The	  significance	  level	  was	  
set	   at	   0.05.	   The	   molar	   concentraOons	   of	   Aβx-­‐40	   and	  
Aβx-­‐42	   were	   calculated.	   The	   percent	   extracOon	   of	  
individual	  Aβ species	  was	  calculated	  according	  to:	  
	  
            Percent extraction = [(Ca-Cv)/Ca] x 100 
	  
NegaOve	   values	   were	   considered	   to	   represent	   a	   net	  
output.	  Daily	  fluxes	  were	  esOmated	  according	  to:	  
	  
            Daily extraction = (Ca-Cv) x organ plasma flow 
	  
For	   the	  purposes	  of	   this	   calculaOon	   the	  cerebral	   and	  
hepaOc	  plasma	  flow	  were	  set	  at	  650L.d-­‐1	  and	  1000	  L/
d-­‐1	  respecOvely.	  
Figure	   3.	   Sampling	   strategy	   for	   organ	   specific	  
arterial	   and	   venous	   plasma.	   Blood	   samples	  
were	   taken	   simultaneously	   from	   catheters	  
inserted	   percutaneously	   and	   posiOoned	   as	  
above.	  	  
Results	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Discussion	  
	  
	  
• This	  is	  the	  first	  afempt	  to	  directly	  quanOfy	  the	  brain-­‐
to-­‐blood	  passage	  of	  Aβ in	  man.	  The	  daily	  cerebral	  
output	  of	  Aβx-­‐40 was	  esOmated	  to	  be	  ≈	  1ng.d-­‐1	  and	  	  that	  
of	  of	  Aβx-­‐41 was	  esOmated	  to	  be	  ≈	  3ng.d-­‐1.	  	  
• Although	  the	  data	  was	  not	  staOsOcally	  significant	  the	  
values	  are	  in	  reasonable	  agreement	  with	  data	  from	  a	  
transgenic	  rat	  model	  of	  ≈	  1.6ng.d-­‐1	  for	  Aβx-­‐40.	  
• There	  are	  two	  main	  limitaOons	  to	  this	  work:	  
i)  The	  main	  limitaOon	  in	  the	  current	  study	  is	  the	  small	  
number	  of	  samples	  available	  which	  has	  affected	  the	  
power	  of	  the	  study.	  	  
ii)  A	  further	  limitaOon	  is	  that	  the	  material	  analysed	  
was	  collected	  in	  connecOon	  with	  	  a	  previous	  study	  
on	  brain	  sterol	  homeostasis.	  	  
• Given	  the	  paucity	  of	  the	  data	  available	  we	  considered	  
it	  prudent	  to	  commence	  these	  invesOgaOons	  on	  a	  pilot	  
basis	  and	  use	  the	  data	  to	  design	  larger	  studies.	  
• Based	  on	  the	  data	  available	  in	  connecOon	  with	  this	  
study	  we	  esOmate	  that	  a	  sample	  size	  of	  40	  would	  be	  
required	  to	  have	  an	  80%	  power	  to	  detect	  a	  	  difference	  
in	  percent	  extracOon	  of	  13.5%.	  	  
• While	  this	  is	  an	  ambiOous	  number	  of	  parOcipants	  for	  a	  
relaOvely	  invasive	  procedure	  we	  believe	  that	  the	  data	  
generated	  would	  be	  very	  valuable	  for	  the	  field	  
Figure	   4.	   Paired	   absolute	   values	   of	   Abx-­‐40/42	   in	  
cerebral	   and	   hepa5c	   plasma.	   In	   the	   cerebral	  
circulaOon,	   greater	   concentraOon	   in	   the	   vein	   is	  
consistent	   with	   output	   while	   the	   opposite	  
applies	   in	   the	   hepaOc	   circulaOon.	   Each	   number	  
corresponds	  to	  an	  individual	  parOcipant.	  
	  
	  
Figure	   5.	   Absolute	   values	   of	   Abx-­‐40/42	   in	   cerebral	   and	  
hepa5c	   plasma	   and	   inter	   oRgan	   fluxes.	   In	   the	   cerebral	  
circulaOon	  a	  negaOve	  percent	  extracOon	  is	  equivalent	  to	  an	  
output	  while	  in	  the	  hepaOc	  circulaOon	  the	  opposite	  applies.	  
No	   staOsOcally	   significant	   difference	  were	   found	  using	   the	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